header
Image from OpenLibrary

A pharmaceutical study on a drug for treatment of a certain ocular disorder / Doaa Abdelmageed Kamel Ahmed ; Supervised Nagwa Hussien Fouda , Randa Tag Abdelrehiem

By: Contributor(s): Material type: TextTextLanguage: English Publication details: Cairo : Doaa Abdelmageed Kamel Ahmed , 2017Description: 180 P. : charts , facsimiles ; 25cmOther title:
  • درا{uئإآ٣}{uئإ٩٤} {uئإآآ}{uئآئئ}{uئإءء}{uئإؤئ}{uئآئئ}{uئإ٩٤} {uئإأآ}{uئإإ٠}{uئإئ٢} {uئإأآ}{uئإؤ٨}{uئإ٨إ}ر {uئإؤئ}{uئإأأ}{uئإئأ}ج ا{uئإآئ}{uئإأ٤}{uئإءإ}اب {uئإ٩١}{uئإ٨إ}{uئإؤئ}{uئإأأ}{uئآئئ}{uئإإ٦} [Added title page title]
Subject(s): Available additional physical forms:
  • Issued also as CD
Dissertation note: Thesis (M.Sc.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutics Summary: Novel sustained release topical drug delivery systems are more preferable than conventional topical dosage forms for ocular administration as they enable dose reduction, patient compliance and avoid the drug loss associated with liquid eye drops.Glaucoma is one of the most serious ocular diseases as it is characterized by increased IOP and optical nerve damage that can lead to blindness, so that it must be under controlled treatment to avoid its complications. Carbonic anhydrase inhibitors are drugs used in treatment of glaucoma by inhibiting the aqueous fluid production resulting in reduction of the elevated IOP. Dorzolamide-HCl is a member of this class of medicaments with potent IOP lowering effect but it should be administered three times daily also its market product Trusopt® causes stinging effect on the eye due to its relatively low pH. Formulation of sustained release formulae for topical administration of Dorzolamide-HCl to be used once daily will avoid the frequent dosing, stinging effect and patient incompliance. Accordingly, our study aims to formulate Dorzolamide-HCl as sustained release formulae and our goal was achieved through this thesis as follows: Chapter I: Formulation and in-vitro evaluation of Dorzolamide-HCl proniosomal gel fotmulae Chapter II: Formulation and in-vitro evaluation of lyophilized Dorzolamide-HCl mini-tablets Chapter III: In-vivo pharmacodynamic evaluation of the selected formulae of Dorzolamide-HCl
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Home library Call number Copy number Status Date due Barcode
Thesis Thesis قاعة الرسائل الجامعية - الدور الاول المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.08.08.M.Sc.2017.Do.P (Browse shelf(Opens below)) Not for loan 01010110074116000
CD - Rom CD - Rom مخـــزن الرســائل الجـــامعية - البدروم المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.08.08.M.Sc.2017.Do.P (Browse shelf(Opens below)) 74116.CD Not for loan 01020110074116000

Thesis (M.Sc.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutics

Novel sustained release topical drug delivery systems are more preferable than conventional topical dosage forms for ocular administration as they enable dose reduction, patient compliance and avoid the drug loss associated with liquid eye drops.Glaucoma is one of the most serious ocular diseases as it is characterized by increased IOP and optical nerve damage that can lead to blindness, so that it must be under controlled treatment to avoid its complications. Carbonic anhydrase inhibitors are drugs used in treatment of glaucoma by inhibiting the aqueous fluid production resulting in reduction of the elevated IOP. Dorzolamide-HCl is a member of this class of medicaments with potent IOP lowering effect but it should be administered three times daily also its market product Trusopt® causes stinging effect on the eye due to its relatively low pH. Formulation of sustained release formulae for topical administration of Dorzolamide-HCl to be used once daily will avoid the frequent dosing, stinging effect and patient incompliance. Accordingly, our study aims to formulate Dorzolamide-HCl as sustained release formulae and our goal was achieved through this thesis as follows: Chapter I: Formulation and in-vitro evaluation of Dorzolamide-HCl proniosomal gel fotmulae Chapter II: Formulation and in-vitro evaluation of lyophilized Dorzolamide-HCl mini-tablets Chapter III: In-vivo pharmacodynamic evaluation of the selected formulae of Dorzolamide-HCl

Issued also as CD

There are no comments on this title.

to post a comment.